Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold

Journal of Medicinal Chemistry

Volumn 44, Issue 8, 2001, Pages 1158-1176

  Stilz, H U ^a   Guba, W ^a   Jablonka, B ^a   Just, M ^a   Klingler, O ^a   Konig W ^a   Wehner, V ^a   Zoller, G ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTYLSERINE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG ACTIVITY; DRUG STRUCTURE; HYDROPHOBICITY; PHARMACOPHORE; PROTEIN MOTIF; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PLATELETS; DOGS; FIBRINOGEN; HUMANS; HYDANTOINS; IMIDAZOLES; INFANT, NEWBORN; MODELS, MOLECULAR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; PROPIONATES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM;

EID: 0035848567     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001068s     Document Type: Article

References (75)

1. Platelet activation in unstable coronary disease
2. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death
3. Role of platelets and antiplatelet agents in cerebrovascular disease: Clues from trials
4. Plaques fissuring - The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina
5. The platelet membrane glycoprotein IIb-IIIa complex
6. Platelet glycoprotein IIb/IIIa antagonists
7. Glycoprotein IIb/IIIa
8. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
9. Platelets in health and disease: Platelet GPIIb-IIIa structure and function: Recent advances in antiplatelet therapy
10. Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary thrombosis
11. Antiplatelet therapies
12. Antiplatelet therapies: From aspirin to GP IIb/IIIa-receptor antagonists and beyond
13. Integrins
14. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa
15. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex with intact platelets
16. Disintegrins: A family of integrin inhibitory proteins from viper venoms
17. Decorsin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor from the leech Macrobdella Decora
18. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro
19. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation
20. Cyclic RGD peptide analogues as antiplatelet antithrombotics
21. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor
22. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor
23. Template-constrained cyclic peptides: Design of high-affinity ligands for GP IIb/IIIa
24. Design and synthesis of novel cyclic RGD containing peptides as highly potent and selective integrin αIIbβ3 antagonists
25. Platelet receptor recognition domain on the γ chain of human fibrinogen and its synthetic peptide analogues
26. Low molecular weight, non-peptide fibrinogen receptor antagonists
27. Sibrafiban
28. Orbofiban Acetate
29. DMP 754
30. Non-peptide fibrinogen receptor antagonists. 2. Optimisation of a tyrosine template as a mimic for Arg-Gly-Asp
31. Non-peptide fibrinogen receptor antagonists. 3. Design and synthesis of a potent, orally active fibrinogen receptor antagonist
32. Design of a new class of orally active fibrinogen receptor antagonists
33. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide
34. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide
35. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore
36. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists
37. Orally active non-peptide fibrinogen receptor (GP IIb/IIIa) antagonists: Identification of 4-[4[4-(Aminoimino-methyl)-phenyl)]-1-piperazinyll-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent
38. A novel series of orally active antiplatelet agents
39. Design and evaluation of nonpeptide fibrinogen γ-chain based GP IIb/IIIa antagonists
40. Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists
41. From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus
42. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists
43. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: Identification of Ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl)imino]methyllphenyll-1,3-thiazol-2-yl]- N-[1-[(ethoxycarbonyl)methyl)piperid-4-yl] amino] propionate (SR 121787) as a potent and long-acting antithrombotic agent
44. SR 121787, a new orally active fibrinogen receptor antagonist
45. Biological characteristics of the new orally active fibrinogen receptor antagonist - S 1762
46. In vitro characterization of S 1197, a novel optically pure diastereomeric fibrinogen receptor antagonist
47. Discovery of an orally active non-peptide fibrinogen receptor antagonist
48. From peptides to heterocyclic petide mimetics-design and synthesis of an orally active fibrinogen receptor antagonist for the prevention of thrombosis
49. From a peptide lead to an orally active peptidomimetic fibrinogen receptor antagonist
50. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
51. Tirofiban: A review of its use in acute coronary syndromes
52. Eptifibatide; platelet antiaggregatory, glycoprotein IIb/IIIa antagonist, fibrinogen receptor antagonist
53. Platelet GPIIb-IIIa blockers
54. Long-term oral platelet glycoprotein IIb/ IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to yield maximum protection from ischemic heart events postacute coronary syndromes (SYMPHONY) trial
55. Lamifiban
56. Cyanation of aromatic halides
57. Über die bildung substituierter hydantoine aus aldehyden und ketonen
58. Nonpeptide glycoprotein IIb/IIIa inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors
59. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore
60. QXP: Powerful, rapid computer algorithms for structure-based drug design
61. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
62. Human platelets possess an inducible and saturable receptor specific for fibrinogen
63. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation
64. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen
65. 3 and glycoprotein IIb-IIIa with fibrinogen: Differential peptide recognition accounts distinct binding sites
66. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide
67. Barbourin - A GP IIb-IIIa-specific integrin antagonist from the venom of SISTRURUS M. BARBOURI
68. Platelets have more than one binding site for von Willebrand factor
69. Inhibition of von Willebrand factor - Platelet interaction by fibrinogen
70. Effects of chymotrypsin and adenosine diphosphate on the exposure of fibrinogen receptors on normal human and glanzmann's thrombasthenic platelets
71. Exposure of platelet fibrinogen receptors by ADP and epinephrine
72. Smart region definition: A new way to improve the predicitive ability and interpretability of three-dimensional quantitative structure - Activity relationships
73. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems